Hospital

Pharmacists and clinicians collaborate to carefully manage rilonacept therapy.

Pulmonary hypertension significantly increases the risk of disease progression and cardiovascular events in patients with myelofibrosis, emphasizing a need for routine screening.

Ropeginterferon alfa-2b shows promising results in treating preprimary myelofibrosis, enhancing clinical responses and safety in patients.

A recent study reveals high RSV antibody levels in older adults, highlighting the importance of vaccination and natural infection for enhanced immunity.

Gianni Scappaticci, PharmD, BCOP, discusses key considerations in therapy selection, limitations of current treatments, and the evolving role of pharmacists in managing chronic graft-vs-host disease (cGVHD) through patient education, adherence support, and integration of emerging therapies.

INCB057643 shows promise in treating myelofibrosis, enhancing anemia and symptom relief.

As compounded medications gain popularity amid drug shortages, concerns about safety, quality, and regulation have intensified, making Pharmacy Compounding Accreditation Board (PCAB) accreditation a safeguard for consistency, oversight, and public trust in compounding pharmacy practices.

A groundbreaking trial shows zimislecel significantly reduces insulin dependence in patients with type 1 diabetes, offering hope for a functional cure.

Shaji Kumar, MD, shares data and insights from the phase 2 RedirecTT-1 study.

The Advisory Committee on Immunization Practices (ACIP) voted 5-1, with 1 voter abstaining, to recommend that adults receive seasonal influenza vaccines that do not contain the preservative thimerosal.

Megan Ehret, PharmD, MS, BCPP, FAAPP, discusses the clinical benefits of long-acting injectables for treating alcohol use disorder and psychiatric conditions, highlighting the pharmacist’s role in improving adherence, addressing stigma, and expanding access to care.

A pharmacist-led program effectively reduces incorrect penicillin allergy labels, promoting better antibiotic use and enhancing patient care in intensive care units.

Pharmacy experts share the benefits of the annual Oncology Pharmacists Connect meeting.

Health care professionals are encouraged to educate patients on potential cannabis-related risks to cardiovascular health.

Combining benmelstobart and anlotinib shows promise for patients with squamous non-small cell lung cancer.

Kevin Chen, PharmD, MS, BCOP, CPP, highlighted key thoracic cancer advances from the 2025 ASCO Annual Meeting.

Scott Soefje, PharmD, MBA, BCOP, shares insights about the evolving role of pharmacists at the 2025 OPC meeting.

New research reveals that combining bimagrumab and semaglutide enhances fat loss while preserving muscle mass, revolutionizing obesity treatment strategies.

HMGCR inhibitors were found to significantly increase the risk of experiencing microvascular complications in patients with diabetes, whereas NPC1L1 inhibitors were found to reduce the risk.

Gabe Hinojosa, PharmD, BCOP, shares key data for pharmacists from the 2025 American Society of Clinical Oncology Annual Meeting.

The session highlighted tirzepatide’s unique mechanism of action, based on comprehensive clinical data and real-world evidence.

Hospitals and health systems proactively monitor and manage data accuracy with third-party administrators to maintain 340B program compliance and maximize benefits for vulnerable patient populations.

Datopotamab deruxtecan gains FDA approval, offering new hope for adults with advanced EGFR-mutated non-small cell lung cancer after prior therapies.

Continuous glucose monitoring (CGM) is poised to transform type 2 diabetes management.